Table 2 Patient characteristics before and after IPTW compared between the thienopyridine and aspirin groups.
Parameter | Total | Unweighted study cohort | Weighted study cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|
Thienopyridine group | vs | Aspirin group | SD | Thienopyridine group | vs | Aspirin group | SD | ||
Patients, no | 520 | 147 | 373 | ||||||
Median age, years (IQR) | 71 (68–74) | 71 (67–74) | 71 (68–74) | − 0.014 | 71 (67–75) | 71 (68–74) | − 0.023 | ||
ASA PS, n (%) | |||||||||
1 | 63 (12) | 17 (11) | 46 (12) | 0.257 | 13% | 12% | 0.013 | ||
2 | 358 (69) | 91 (62) | 267 (72) | 67% | 69% | ||||
3, or more | 99 (19) | 39 (27) | 60 (16) | 20% | 19% | ||||
BMI ≧ 25 kg/m2, n (%) | 204 (39) | 50 (34) | 154 (41) | − 0.151 | 38% | 39% | − 0.015 | ||
KDIGO CKD grade (eGFR), n (%) | |||||||||
Grade 1, or 2 (60 mL/min/1.73 m2, or more) | 333 (64) | 89 (61) | 244 (65) | 0.101 | 65% | 64% | − 0.020 | ||
Grade 3a, or 3b (30–59 mL/min/1.73 m2) | 172 (33) | 51 (35) | 121 (32) | 32% | 33% | ||||
Grade 4, or 5 (29 mL/min/1.73 m2, or less) | 15 (2.9) | 7 (4.7) | 8 (2.1) | 3.4% | 3.1% | ||||
NCCN risk classification group, n (%) | |||||||||
Low | 15 (2.9) | 4 (2.9) | 11 (3.0) | 0.074 | 2.6% | 3.0% | 0.002 | ||
Intermediate | 257 (49) | 69 (47) | 188 (40) | 49% | 49% | ||||
High, or more | 248 (48) | 74 (50) | 174 (47) | 48% | 48% | ||||
Pelvic lymph node dissection, n (%) | |||||||||
None | 269 (51) | 75 (51) | 194 (52) | − 0.126 | 52% | 53% | − 0.040 | ||
Limited | 144 (28) | 47 (32) | 97 (26) | 29% | 27% | ||||
Extended | 107 (21) | 25 (17) | 82 (22) | 19% | 20% | ||||
Neurovascular bundle preservation, n (%) | 154 (30) | 46 (31) | 108 (29) | 0.051 | 29% | 29% | 0.040 | ||
Preoperative hormonal therapy, n (%) | 132 (25) | 32 (22) | 100 (27) | − 0.118 | 27% | 26% | 0.024 | ||
Perioperative continuation of antiplatelets, n (%) | 133 (26) | 25 (17) | 108 (29) | − 0.287 | 24% | 26% | − 0.036 | ||
